Clinical Trials Directory

Trials / Unknown

UnknownNCT06070103

Depression ,Anxiety and Stress Disorders Among Diabetic Patients in Assuit University Hospitals

Depression, Anxiety and Stress Disorders Among Diabetic Patients in Assuit University Hospitals

Status
Unknown
Phase
Study type
Observational
Enrollment
325 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers

Summary

1. Assessment the prevalence of psychiatric disorders in diabetic patient in Assuit University Hospital. 2. Determine the associated factors with the psychiatric disorders.

Detailed description

Across the world, both Diabetes and Psychiatric disorders are on rise. Diabetes strongly affects disability, mortality, and global health expenditure. Diabetes mellitus is a disabling long-term health condition that is common and growing. Globally, it affects 10.5% of the population and is the leading cause of lost disability-adjusted life years Type 1 diabetes is a lifelong autoimmune disease characterized by insulin deficiency and resultant hyperglycemia. It constitutes around 10% of all diagnosed cases of diabetes and its incidence is increasing globally. Type 2 diabetes mellitus (DM2) is a chronic metabolic disease characterized by an increase in normal serum glucose levels (hyperglycemia). Psychological disorders can occur in people with diabetes of all ages. Type 1 diabetes seems to have a higher prevalence of psychological disorders than type 2 diabetes. About 15%-20% of people with diabetes are suffering from depression. the exact cause of depression in people with diabetes is unknown, it is likely complex due to a combination of genetic, physiological, and psychological factors. Depression and anxiety could worsen the prognosis of diabetes by reducing the patients' ability to self-care and increasing non-compliance to treatments while increasing the risk of serious short-term and long-term complications such as blindness, amputations, stroke, and even premature death.

Conditions

Timeline

Start date
2024-04-01
Primary completion
2024-11-30
Completion
2024-12-31
First posted
2023-10-06
Last updated
2024-02-28

Source: ClinicalTrials.gov record NCT06070103. Inclusion in this directory is not an endorsement.